0RRB Stock Chart & Stats
CHF11.00
-CHF0.09(-0.85%)
At close: 4:00 PM EDT
CHF11.00
-CHF0.09(-0.85%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF16.42
Previous CloseN/A
Volume26.13K
Average Volume (3M)59.15K
Market Cap
CHF798.11M
Enterprise ValueCHF604.15M
Total Cash (Recent Filing)CHF89.80M
Total Debt (Recent Filing)CHF265.68M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 18, 2027EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)-1.58
Shares Outstanding54,000,000
10 Day Avg. Volume61,660
30 Day Avg. Volume59,148
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF13.27Price Target Upside20.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.66
Revenue Forecast (FY)CHF1.26B
Bulls Say, Bears Say
Bulls Say
Prescription GrowthPrescription growth is supported by stronger customer retention, not only higher order volume: newer Rx cohorts retain at materially higher rates. That can raise customer lifetime value, deepen the pharmacy relationship, and provide a durable base for further cross-selling as e-prescription adoption expands.
Digital Health ExpansionRapid growth in Digital Services and TeleClinic broadens DocMorris beyond product fulfillment into recurring healthcare interactions. The reported treatment and revenue expansion, alongside higher TeleClinic EBITDA, indicates scalable platform economics and greater opportunities to cross-sell pharmacy products.
Operating LeverageThe AI-First program provides a defined, multi-year efficiency opportunity rather than relying solely on revenue growth. Recurring savings and lower capital expenditure could improve margins, reduce cash needs, and support management’s stated path toward EBITDA breakeven in 2026.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow limits DocMorris’s ability to fund expansion internally. The sharp 2025 deterioration increases dependence on liquidity or external financing, while continued investment in growth remains important before the targeted 2027 free-cash-flow breakeven.
Loss-making OperationsOngoing operating losses weaken confidence in the durability of earnings and reduce the company’s ability to absorb execution setbacks. Although recent margins are improving, the negative 2024–2025 results show that revenue growth has not yet translated into sustainable profitability.
Regulatory PressureChanges to German pharmacy remuneration and higher patient co-payments could pressure economics and make customers more price-sensitive. These structural policy effects may constrain prescription profitability, complicate pricing and exemption decisions, and weigh on growth as reforms take effect.
DocMorris News
0RRB FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest share price was CHF3.92 and its highest was CHF16.41 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF798.11M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Mar 18, 2027 which is in 146 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Aug 19, 2026. The company reported -CHF1.1 earnings per share for the quarter.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG pays a Notavailable dividend of CHF0.285 which represents an annual dividend yield of 0.22%. See more information on DocMorris AG dividends here
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -0.58.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 54,000,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -CHF1.1 in its last earnings report. Following the earnings report the stock price went down -1.237%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in GB:0RRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
0RRB Stock 12 Month Forecast
Average Price Target
CHF13.27
▲(20.64% Upside)